Discover what healthcare professionals (HCPs) think about pharmaceutical products and their manufacturers, as it happens, through CREATION.co’s tracking updates. How are HCPs responding to drug launch news? How are HCPs talking about or engaging with the Top 50 pharma companies on social media? Each week, CREATION.co’s tracking updates bring you the latest insights from the conversation of HCPs across the globe discussing these topics and more.
The Top 50 Pharmaceutical Companies mentioned by HCPs on Twitter
|August Rank||July Rank||Company |
|3||3||Johnson & Johnson||715||206||40|
|11||13||Merck & Co||236||132||5|
The latest insights from HCPs mentioning the Top 50 Pharmaceutical Companies
The five pharmaceutical companies that were mentioned the most by HCPs on Twitter during August 2022 were Pfizer, Moderna, Johnson & Johnson, AstraZeneca and Eli Lilly.
The number of mentions of pharmaceutical companies identified by CREATION.co in August 2022 remained largely unchanged from the previous month with the only notable difference being the rise in online mentions of Eli Lilly, causing it to climb into the top 5 most mentioned pharmaceutical companies by HCPs online.
Moderna remained the second most mentioned pharmaceutical company with HCPs sharing tweets about Moderna’s campaign to claim sole rights to the mRNA COVID-19 vaccine technology.
Moderna is suing rival Covid-19 vaccine makers Pfizer and BioNTech, alleging their shot infringed on key patents involving mRNA technology https://t.co/ewhwTGH8UC
— The Wall Street Journal (@WSJ) August 26, 2022
Between ads on Youtube and having a stand at the US Open 🎾, Moderna really is on a PR campaign to claim sole rights to mRNA vaccine technology and erase any memory of the public funding and operation warp speed $ that helped develop mRNA technology in the first place. pic.twitter.com/4T0Ds3s5Eo
— Tahir Amin (@realtahiramin) August 30, 2022
The top shared links by HCPs discussed:
- A Press Announcement from the FDA announcing the authorisation of Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for use as a booster dose.
- A Twitter event post about the US FDA’s authorisation of Pfizer and Moderna’s updated COVID-19 boosters targeting Omicron subvariants.
- A News Article from the BBC about COVID-19 vaccine technology.
One of the key drivers of conversation in August 2022 came from HCP discussions about the approval of Moderna’s bivalent COVID-19 vaccine in the United Kingdom. HCPs retweeted the announcement of the approval made by @MHRAgovuk – Medicines & Healthcare products regulatory agency.
The UK has just approved an updated Omicron-specific COVID-19 vaccine (BA.1).
This vaccine has already been mass produced.
Two BA.1 specific ("bivalent") vaccines are under review at Health Canada at the moment:
1. Moderna – submitted June 30
2. Pfizer – submitted on July 25 https://t.co/wNuNJvmNmN
— Isaac Bogoch (@BogochIsaac) August 15, 2022
HCPs including Dr Megan Ranney shared positive views about the approval of the vaccine, calling the approval ‘big news’. Additionally, Dr Megan Ranney, shared a Twitter thread about “What do I do this fall”. The thread encouraged her followers to think about the need for vaccine updates and boosters to improve efficacy against existing and future variants.
Big news yesterday from the UK: @moderna_tx bivalent (BA1/wild type) #covid19 vaccine was approved!
But in the US, it's different.
🧵A thread on how to think about "what do I do this fall":https://t.co/MwNZIJ2hmP
— Megan Ranney MD MPH 🌻 (@meganranney) August 16, 2022
Eli Lilly made its way into the top 5 most mentioned pharmaceutical companies by HCPs in August 2022. HCPs mentioned Eli Lilly when discussing advances in their obesity treatment tirzepatide. HCPs were excited and positive about advances in treatment sharing that forthcoming indications are moving full steam ahead with great momentum and a bright future, also, stating that obesity treatment is entering an exciting new era.
As #obesity treatment enters an exciting new era, we are reminded of the lessons taught by “how bariatric surgery works @seeleyrj et al” and that pharma has developed temporary “yet BRILLIANT” fixes @LillyPad @novonordiskmed based on the SCIENCE of obesity causes and treatments https://t.co/N5D1CBN0zT
— Neil Floch MD (@NeilFlochMD) August 20, 2022
Majority of @LillyPad conference call was devoted to Tirzepatide. The market share of GLP-1RAs continues to increase substantially #T2D #obesity with new indications forthcoming. After 17 years in the clinic the GLP-1 based medicine train has great momentum and a bright future pic.twitter.com/7o02PUiMPI
— Daniel J Drucker (@DanielJDrucker) August 4, 2022
CREATION.co continues to analyse online HCP conversation on a variety of topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights.
To stay up to date, you can sign up to CREATION.co’s monthly eJournal.
- In August 2022, CREATION Pinpoint® identified 11,240 healthcare professional (HCP) authored tweets from 5,201 individual HCPs mentioning a Top 50 Pharmaceutical company (according to revenue).
- Data for this research was analysed from the online Twitter conversations of HCPs in all languages mentioning a Top 50 Pharmaceutical company between 01 August and 31 August 2022.
- Unless otherwise specified, mentions of a company are not limited to its Twitter account(s).
- In some cases, a tweet may mention more than one company account (e.g. @abbottnews and @abbottglobal) – this only counts as one Company Mention and Account Mention.
- Johnson & Johnson was included as a whole, encompassing its pharmaceutical subsidiary, Janssen. In August 58 of these posts mentioned Janssen.